PM&R and Physiatry Billing: The 2026 Guide to Codes, Prior Auth and Denials

Why Physiatry Billing Isn't Physical Therapy Billing, and What That Mix-Up Costs a Rehab Practice in EMG, Injection and E/M Revenue

By Team Rcmaxis  ·  November 4, 2026  ·  12 min read

A physiatrist who runs a four-limb nerve conduction study bills CPT 95913. At the 2026 Medicare conversion factor of $33.4009 and a non-facility total RVU of 8.98, that single study pays close to $300 a visit. Run four of those a week and the EMG lab alone is worth roughly $62,000 a year in collections, assuming clean claims and no denials. Most PM&R practices don't get clean claims, because the billing office is treating physiatry like physical therapy, and the two run on completely different rules.

Physical medicine and rehabilitation is a physician specialty: an MD or DO billing E/M visits, EMG and nerve conduction studies, and procedures like botulinum toxin injections for spasticity under the physician fee schedule. That's a different payment system than a physical or occupational therapist billing timed treatment codes under the 8-minute rule, which is what our physical therapy billing guide covers. When a billing team applies therapy-style logic, modifier habits, visit caps, documentation shortcuts, to physician-level codes, the claims that fall out are EMG studies without a defensible medical-necessity note, injection codes stacked without the right modifier, and E/M visits billed (or left unbilled) without the complexity the record actually supports.

The Codes That Carry Physiatry Revenue, and Where They Break

Four code families drive most physiatry collections, and each has its own failure pattern. Nerve conduction studies and needle EMG (the 95907 through 95913 range) scale by the number of nerves or muscles tested, so the documentation has to justify the count, not just the diagnosis. A claim for a four-limb study on a patient with a one-sided complaint invites a medical-necessity denial, because the record doesn't explain why the unaffected side was tested. Repeat studies are the sharper edge: a second EMG on the same nerve distribution without a new or worsening symptom, a surgical change, or a specific treatment-decision question is one of the most reliable denial triggers in the specialty, and it's exactly the pattern Medicare contractors have flagged for years.

Chemodenervation for spasticity (CPT 64642 for one extremity with one to four muscles, 64644 for one extremity with five or more, plus add-on codes 64643 and 64645 for each additional extremity) pays for the injection procedure itself, separate from the toxin. The drug gets billed on its own HCPCS code, J0585 for onabotulinumtoxinA (Botox), J0586 for abobotulinumtoxinA (Dysport), billed per unit administered, with wasted single-use vial product tracked separately under current JW and JZ modifier rules. Neither code family carries modifier 50 for bilateral billing; CMS guidance is explicit that modifier 50 doesn't apply to 64642 through 64647 at all, so a claim that tries to double the extremity codes with a bilateral modifier instead of the correct add-on code gets rejected on the edit, not on medical necessity.

Trigger Point Injections and the Same-Day E/M Problem

Trigger point injection coding (CPT 20552 for one or two muscles, 20553 for three or more) sits in one of the more contested corners of PM&R billing. Sources disagree on whether modifier 59 belongs on 20552 or 20553 when a physiatrist injects multiple separate anatomic sites in one visit; some coding guidance allows it with clear separate-site documentation, while other current coding alerts argue Medicare's zero-day global period on these codes means modifier 59 shouldn't be used on either code regardless of documentation. Until your MAC's current policy and the NCCI Policy Manual say otherwise, the safer posture is to document the specific anatomic sites in enough detail that the claim doesn't need to lean on a contested modifier to get paid.

The same-day E/M question has a cleaner answer. CMS guidance (MLN1783722) is direct: modifier 59 does not go on an E/M line at all. If a physiatrist performs a separately identifiable E/M service, a new complaint, a medication review, a functional reassessment that isn't just the pre-procedure workup, on the same day as an injection, that visit gets modifier 25, not 59. The documentation has to show the E/M did real, distinct work beyond what's already bundled into the injection code's global package. A visit note that just restates the history leading into the injection, with no separate assessment or plan, won't survive a payer's modifier 25 audit, and those audits are routine, not rare, for specialties that bill procedures and E/M together as often as PM&R does.

Prior Authorization: What Actually Triggers It, and What the Request Needs

Commercial and Medicare Advantage payers build botulinum toxin prior authorization around a documented therapy trial, not a specific visit count in most policies reviewed: the request has to show the patient is enrolled in, or has completed, physical or occupational therapy for the spasticity, plus (for many plans) a documented trial and failure of oral antispasmodics like baclofen or tizanidine before the toxin injection gets approved. Some plans carve out preferred products, Botox and Xeomin without prior auth on certain formularies, while Dysport and Myobloc sit in non-preferred tiers that require it. That preferred-product distinction changes by plan and by year, so verify it against the specific payer's current policy before you schedule the injection, not after the claim denies.

EMG and nerve conduction studies follow a different trigger: it's repetition, not the first study, that draws scrutiny. A first EMG/NCS tied to a clear referring diagnosis rarely needs prior auth from Medicare, though Medicare Advantage and commercial plans increasingly require it. A second or third study on the same patient needs a note that documents what changed, a new symptom, a surgical intervention, a treatment decision that depends on the result, since "we always repeat it at six months" isn't medical necessity on its own. Track the authorization's expiration date separately from the procedure count; a plan that approves "one study within 90 days" denies the claim if the study happens on day 91, even though the clinical indication never changed.

Where PM&R Overlaps With Inpatient Rehab, and Why That's a Different Bill

A lot of physiatrists split time between outpatient EMG and injection clinics and inpatient rehabilitation facility (IRF) consults, often serving as the IRF medical director or attending of record. That inpatient work bills under an entirely different structure than the facility's own IRF-PAI-driven payment, which our IRF billing guide covers from the facility side. The physician's professional fee for IRF admission and daily visits follows standard E/M rules (initial hospital inpatient or observation care codes, subsequent care codes), billed separately from the facility's case-mix-adjusted IRF payment. Billing teams that only track the facility side miss physician revenue; billing teams that only track physician E/M miss the fact that a patient's IRF length-of-stay and functional-outcome documentation (used for the facility's own case-mix group) depends partly on the physiatrist's own notes being specific enough to support it.

Time-based procedure codes create a second overlap worth tracking carefully. When a physiatrist personally performs a timed procedure, certain manual therapy or neuromuscular reeducation codes in the 97000 series, rather than delegating it to PT or OT staff, Medicare's 8-minute rule still applies: timed-code minutes for the date of service get pooled, converted to units using the CMS Publication 100-04, Chapter 5, Section 20.2 threshold table (one unit for 8 to 22 minutes, a second unit from 23 to 37, and so on), and billed as a single total rather than unit-per-code. Commercial payers often use the AMA's different "Rule of Eights" instead, which counts each code separately and can produce a different unit count for the identical visit. Billing the wrong rule's unit count to the wrong payer is a quiet, recurring source of underpayment that rarely triggers a denial, it just pays less than it should, which makes it easy to miss without a periodic claims audit.

Audit Exposure: What EMG and Injection Billing Patterns Draw Scrutiny

EMG and nerve conduction study billing has a long history of federal audit attention, even though we found no dedicated, dated 2026 OIG Work Plan item specific to physiatry, and we're saying that plainly rather than inventing a citation that doesn't exist. OIG flagged medical necessity of nerve conduction studies as far back as 2004, citing a steep rise in Medicare-allowed amounts, and electrodiagnostic coding showed up again in the 2013 and 2014 Work Plans. A specific audit marker from OIG's own review work has stuck around since: practices with an unusually high share, over 90%, of electrodiagnostic claims that bill a nerve conduction study without a matching needle EMG (or vice versa) get flagged for unusual billing patterns, because a complete study typically includes both components when clinically indicated. On the enforcement side, a Louisiana clinic and physician settled a False Claims Act matter over nerve conduction studies billed as if they were covered diagnostic tests when they were, per OIG, non-covered screening exams.

The standard 36-month claims lookback applies here the same way it applies to every other specialty: if your practice has been running a high volume of repeat EMG/NCS or stacking chemodenervation claims without extremity-count documentation that matches the chart, every claim inside that window is exposed, whether or not a current, dated Work Plan item names PM&R specifically. Waiting for OIG to publish something before fixing the documentation pattern means carrying exposure for no reason.

Building a Physiatry Billing Workflow That Actually Holds Up

Start by splitting the chart template so physician documentation never borrows therapy-note language. A note that reads like a PT flowsheet, "patient tolerated treatment well," with no distinct physician assessment, won't support an E/M charge even when the physiatrist genuinely did separate, billable work. Build a short macro for each repeat-procedure scenario, repeat EMG, second-round chemodenervation, that forces the documenting physician to name the specific clinical reason for repeating the study or injection, not just copy the prior note forward.

Second, build the extremity and muscle count into the coding workflow itself rather than leaving it to whoever submits the claim. A chemodenervation note that states "four extremities, 12 total muscles" should map to a specific, repeatable code combination every time; if your EHR's order set doesn't force that level of specificity, your coders are guessing, and guesses are what turn into post-payment audit findings eighteen months later. Our billing modifiers guide covers the broader modifier 25/59/XS decision tree this specialty leans on constantly, worth a look alongside this one if your denial rate on injection-plus-E/M claims is already running high.

Frequently Asked Questions About PM&R and Physiatry Billing

Is PM&R billing the same as physical therapy billing?

No, and mixing the two up is where a lot of denials start. A physiatrist is an MD or DO billing under the physician fee schedule for E/M visits, EMG and nerve conduction studies, and injection procedures like chemodenervation for spasticity. A physical therapist bills timed treatment codes under the therapy fee schedule and is subject to the Medicare 8-minute rule. The same patient can generate claims under both models in the same episode of care, and payers scrutinize whether the physician visit added distinct, separately billable value beyond the therapy plan of care.

Can I bill an E/M visit on the same day as a trigger point or spasticity injection?

Yes, if the E/M work is genuinely separate from the pre-, intra- and post-procedure work bundled into the injection code, and you append modifier 25 to the E/M line. CMS guidance is explicit that modifier 59 does not belong on an E/M line; same-day E/M alongside a procedure is a modifier 25 question, not a modifier 59 question. Documentation has to show the E/M was its own distinct, medically necessary service, not a restated history leading into the injection.

Does Medicare require prior authorization for EMG and nerve conduction studies?

Traditional Medicare generally does not require prior authorization for EMG/NCS, but Medicare Advantage plans and most commercial payers do, especially for repeat studies on the same patient. Payers typically want the referring diagnosis, the specific nerves or muscles to be tested, documented symptoms that have changed or persisted since any prior study, and a note explaining why the result will change management. A repeat study without a new or worsening symptom is one of the most common denial triggers in this specialty.